tbuckley/cabot-search huggingface dataset:
PP.24 High Correlation With KRAS and PDL-1 in Lung Adenocarcinoma of a Single Institution
Authors: Bruna Motke, Manuela Zereu, Spencer Marcantonio Camargo, Jose Felicetti, Bruna Santin, Luiza Andres, Fabiola Perin, Stephan Soder
Journal: Journal of Thoracic Oncology (2023)
PD.01.02 Novel MicroRNAs Identified in Lung Cancer and Associated With Malignant Metabolism (In Silico)
Authors: Ana Laura Seneda, Iael W. Minutentag, Mateus Barros-Filho, Vanessa das Graças Pereira de Souza, Wan Lam, Sandra Aparecida Drigo, Luis A.J. Mur, Patricia P. Reis
Journal: Journal of Thoracic Oncology (2023)
PP.14 Real World Data of Patients ≥ 80 Years Old With Metastatic NSCLC: Evaluation of an Underrepresented Population in Clinical Trials
Authors: Filipe Visani, Tatiane Montella, Rafael Duarte Paes, Nathalia Gimenes Afonso, Izabella Negreiros, Pedro De Marchi, Carlos Gil Ferreira, Rodrigo Dienstmann
Journal: Journal of Thoracic Oncology (2023)
PP.33 Effect of Age on Incidences of Peri-Operative Outcomes after Robotic-Assisted Video-Thoracoscopic Pulmonary Lobectomy
Authors: Kristie Labib, William West, Cole Fiedler, Lauren Ladehoff, William Doyle, Jose Malavet, Jenna Marek, Allison Dumitriu Carcoana, Carla Moodie, Joseph Garrett, Jenna Tew, Jobelle Baldonado, Jacques Fontaine, Eric Toloza
Journal: Journal of Thoracic Oncology (2023)
PP.28 Underutilization of Systemic Therapy in Patients Undergoing Pneumonectomy: A Missed Opportunity for Survival
Authors: Jorge Humberto Rodriguez Quintero, Mohamed Kamel, Mostafa Elbahrawy, John Skendelas, Marc Vimolratana, Neel Chudgar, Brendon Stiles
Journal: Journal of Thoracic Oncology (2023)
PP.17 Stereotactic Ablative Radiotherapy in Oligometastatic Pulmonary Disease. First Institutional Experience
Authors: Ariel Gomez Palacios, Cecilia Rios, Belen Raiden, Crista Zelada, Iara Rivas, Diego Fernandez, Lucas Caussa, Ofelia Perez Conci, Maria Fernanda Diaz Vazquez, Gustavo Ferraris
Journal: Journal of Thoracic Oncology (2023)
PP.35 Preoperative Blood-Urea-Nitrogen-to-Serum-Albumin Ratio Is Not a Predictor of Worse Outcomes After Robotic-Assisted Pulmonary Lobectomy for Lung Cancer
Authors: Allison Dumitriu Carcoana, Jenna Marek, Jose Malavet, William Doyle, Carla Moodie, Joseph Garrett, Jenna Tew, Jobelle Baldonado, Jacques Fontaine, Eric Toloza
Journal: Journal of Thoracic Oncology (2023)
PP.11 Effectiveness of Ramucirumab Plus Docetaxel for Advanced Non-Small Cell Lung Cancer Patients: a Cohort of 93 Patients
Authors: Isabella Favato Barcelos, Pedro De Marchi, Pedro Nazareth Aguiar Junior, Tatiane Caldas Montella, Nathalia Gimenes Afonso, Filipe Visani, Izabella Santos Negreiros, Clarissa Maria de Cerqueira Mathias, Rafael Duarte Paes, Rodrigo Dienstmann, Carlos Gil Ferreira
Journal: Journal of Thoracic Oncology (2023)
PD.01.01 Acquired EGFR Resistant Mutations and Co-mutations in Tumors Of Non-small Cell Lung Cancer Patients Treated With Tyrosine Kinase Inhibitors (TKI)
Authors: Luis E. Raez, Yasmine Baca, Carlos Carracedo, Ari Vanderwalde, Chadi Nabhan, Misako Nagasaka, Jorge Nieva, Hirva Mandani, Hossein Borghaei, Mark Socinski, Hina Khan, Antoinette Wozniak, Gilberto Lopes, Stephen Liu
Journal: Journal of Thoracic Oncology (2023)
PP.10 Role of the Neutrophil-Lymphocyte Elationship in Patients With Advanced NSCLC Treated With Immunotherapy
Authors: Eduardo Richardet, I. Magi, V. Peruchin, P. Perea, A. Tello, M. Molina, L. Acosta, M. Paradelo, M. Richardet
Journal: Journal of Thoracic Oncology (2023)
JAAD Case Reports article list
Authors: Allyson Yelich, Summer Moon, Martina Burlando, Ilaria Salvi, Antonio Guadagno, Emanuele Cozzani, Aurora Parodi, Joo Jung, Meredith Park, Hesham Alshaikh, Heather O'connor, Dirk Elston, Giovanni Paolino, Valentina Caputo, Giorgio Stabile, Emanuela Bonoldi, Franco Rongioletti, Suzanne Xu, Katharine Ellis, Simon Roy, Margaret Johnston, Amanda Zubek, Caitlyn Kellogg, Elise Burger, Brian Hinds, Jeremy Schneider, Angela Moore, Kara Hurley, Abdullah Al-Omair, Muteb Alharbi, Asem Almesfer, Chelsea Shope, Laura Andrews, Melissa Cunningham, Jessica Connett, Nicole Trupiano, Erika Koeppe, Michelle Jacobs, Tobias Else, Kelly Cha, Bianca Biglione, Bethany Cucka, Connie Shi, Daniela Kroshinsky, Kelly Young, Naomi Briones, Elisabeth Pedersen, Douglas Fullen, Frank Wang, Arman Torosian, Long Ly, Andrea Murina, Carole Bitar, Peter Ch'en, Eingun Song, Neha Narayan, Benjamin Williams, Brea Lipe, Anna De Benedetto, Stephanie Matthews, Vincent Ho, Sarah Pourakbar, Atieh Jibbe, Ashmi Patel, Haneen Salah, Remi Hamel, Elizabeth Hall, Suzanne Crumley, Karen Woods, Leonard Goldberg, Alexa Demaio, Kimberly Hashemi, Alexandria Avery, John Metcalf, Laura Winterfield, Soundos Youssef, Lindsey Bordone, Pushkar Aggarwal, Emily Gorell, Kelsey Flood, Kerith Spicknall, Debra Breneman, Emily Hong, Ronghua Hu, Alba Posligua, Keith Choate, John Durkin, Autumn Saizan, Owen Dean, Glynis Scott, Kathleen Mannava, Mary Mercurio, Amanda Ramnot, Sydney Do, Barry Resnik, John Broderick, Mary Mcdaniel, Bradley Lloyd, Craig Rohan, Chiamaka Okorie, Iman Salem, Matthew Davis, Julianne Mann, Nadav Friedel, Elisa Gallo, Tamir Horovitz, Ronen Ami, Eli Sprecher, Moshe Bressler, Axel Delgado, Nelson Charlie, Alexa Carboni, Daren Fomin, Justin Qian, Jeffrey Li, Elysha Rose, Travis Vandergriff, Leticia Khosama, Muhammad Beg, Melissa Mauskar, Richard Wang, Daniel Eriksson, David Gyll, Marie Virtanen, Niklas Dahl, Joakim Klar, Eva-Lena Stattin
Journal: Journal of the American Academy of Dermatology (2023)
PP.01 Study Evaluating Alectinib Pharmacokinetics in the Hispanic Population With Advanced ALK-Rearranged Non-small-Cell Lung Cancer
Authors: Oscar Arrieta, Luis Lara-Mejía, Patricia García López, Norma Hernández-Pedro, Graciela Cruz-Rico, David Heredia, Roberto Sánchez-Reyes, Cesar Infante-González, Aida Martínez Pérez, Venecia Matías-Cruz, Denise López Sámchez, Andres Cardona
Journal: Journal of Thoracic Oncology (2023)
PP.38 Unusual Location of Thymic Carcinoma and It’s Surgical Management
Authors: Emmanuel Peña Gomez Portugal, Luis M.M. Solorzano Campos, Emmanuel Hernandez Arguello, Nayeli Itzel Escalante Quesada, J Arciniega Dominguez, Alma Solano Nieto
Journal: Journal of Thoracic Oncology (2023)
PD.02.05 EGFR Exon 20 Insertion Mutations in a Brazilian Lung Cancer Cohort: Challenges for the Identification and Clinical Features
Authors: Izabella Negreiros, Tatiane Montella, Lucas Silva Silva, Rafael Duarte Paes, Mariano Zali, Layla Galindo, Filipe Visani, Nathalia Gimenes Afonso, Pedro De Marchi, Carlos Gil Ferreira, Rodrigo Dienstmann
Journal: Journal of Thoracic Oncology (2023)
PP.23 GALNT13 Detection in Liquid Biopsy in Non-Small Cell Lung Cancer (NSCLC) Patients
Authors: Eugenia Fernandez Armua, Diego Touya, Diego Santana, Mariana Carrasco, Marcos Acosta, Valeria Braga, Eduardo Osinaga, Nora Berois
Journal: Journal of Thoracic Oncology (2023)
PP.31 Marital Status Shows No Protective Effect on Perioperative Outcomes After Robotic-Assisted Pulmonary Lobectomy
Authors: Jenna Marek, Allison Dumitriu Carcoana, William West, Emily Weeden, Ajay Varadhan, Jessica Cobb, Sarah Cool, Gregory Fishberger, Collin Chase, Maykel Dolorit, Harrison Strang, Carla Moodie, Joseph Garrett, Jenna Tew, Jobelle Baldonado, Jacques Fontaine, Eric Toloza
Journal: Journal of Thoracic Oncology (2023)
Relaxin-encapsulated polymeric metformin nanoparticles remodel tumor immune microenvironment by reducing CAFs for efficient triple-negative breast cancer immunotherapy
Authors: Hongyan Zhang, Liying Chen, Yue Zhao, Ningchao Luo, Jingbin Shi, Shujun Xu, Lisha Ma, Menglin Wang, Mancang Gu, Chaofeng Mu, Yang Xiong
Journal: Asian Journal of Pharmaceutical Sciences (2023)

Cancer-associated fibroblasts (CAFs) are one of the most abundant stromal cells in the tumor microenvironment which mediate desmoplastic response and are the primary driver for an immunosuppressive microenvironment, leading to the failure of triple-negative breast cancer (TNBC) immunotherapy. Therefore, depleting CAFs may enhance the effect of immunotherapy (such as PD-L1 antibody). Relaxin (RLN) has been demonstrated to significantly improve transforming growth factor-β (TGF-β) induced CAFs activation and tumor immunosuppressive microenvironment. However, the short half-life and systemic vasodilation of RLN limit its in vivo efficacy. Here, plasmid encoding relaxin (pRLN) to locally express RLN was delivered with a new positively charged polymer named polymeric metformin (PolyMet), which could increase gene transfer efficiency significantly and have low toxicity that have been certified by our lab before. In order to improve the stability of pRLN in vivo, this complex was further formed lipid poly-γ-glutamic acid (PGA)/PolyMet-pRLN nanoparticle (LPPR). The particle size of LPPR was 205.5 ± 2.9 nm, and the zeta potential was +55.4 ± 1.6 mV. LPPR displayed excellent tumor penetrating efficacy and weaken proliferation of CAFs in 4T1luc/CAFs tumor spheres in vitro. In vivo, it could reverse aberrantly activated CAFs by decreasing the expression of profibrogenic cytokine and remove the physical barrier to reshape the tumor stromal microenvironment, which enabled a 2.2-fold increase in cytotoxic T cell infiltration within the tumor and a decrease in immunosuppressive cells infiltration. Thus, LPPR was observed retarded tumor growth by itself in the 4T1 tumor bearing-mouse, and the reshaped immune microenvironment further led to facilitate antitumor effect when it combined with PD-L1 antibody (aPD-L1). Altogether, this study presented a novel therapeutic approach against tumor stroma using LPPR to achieve a combination regimen with immune checkpoint blockade therapy against the desmoplastic TNBC model.
Targeting FABP4 in elderly mice rejuvenates liver metabolism and ameliorates aging-associated metabolic disorders
Authors: Jian Lv, Yimeng Hu, Lili Li, Yuan He, Jingjing Wang, Ningning Guo, Yu Fang, Qin Chen, Cheguo Cai, Jingjing Tong, Lixu Tang, Zhihua Wang
Journal: Metabolism (2023)
Mesoporous silica nanoparticles with chiral pattern topological structure function as “antiskid tires” on the intestinal mucosa to facilitate oral drugs delivery
Authors: Wei Xin, Lin Wang, Jiahui Lin, Yanbu Wang, Qi pan, Yang Han, Zhiye Bao, Shun Zong, Ying Cheng, Xuchun Chen, Lin Zhao, Heran Li
Journal: Asian Journal of Pharmaceutical Sciences (2023)

The weak adhesion between nanocarriers and the intestinal mucosa was one of the main reasons caused the failure in oral delivery. Inspired by the "antiskid tires" with complex chiral patterns, mesoporous silica nanoparticles AT-R@CMSN exhibiting geometrical chiral structure were designed to improve the surface/interface roughness in nanoscale, and employed as the hosting system for insoluble drugs nimesulide (NMS) and ibuprofen (IBU). Once performing the delivery tasks, AT-R@CMSN with rigid skeleton protected the loaded drug and reduced the irritation of drug on gastrointestinal tract (GIT), while their porous structure deprived drug crystal and improved drug release. More importantly, AT-R@CMSN functioned as "antiskid tire" to produce higher friction on intestinal mucosa and substantively influenced multiple biological processes, including "contact", "adhesion", "retention", "permeation" and "uptake", compared to the achiral S@MSN, thereby improving the oral adsorption effectiveness of such drug delivery systems. By engineering AT-R@CMSN to overcome the stability, solubility and permeability bottlenecks of drugs, orally administered NMS or IBU loaded AT-R@CMSN could achieve higher relative bioavailability (705.95% and 444.42%, respectively) and stronger anti-inflammation effect. In addition, AT-R@CMSN displayed favorable biocompatibility and biodegradability. Undoubtedly, the present finding helped to understand the oral adsorption process of nanocarriers, and provided novel insights into the rational design of nanocarriers.
Sustained Release of Human Adipose Tissue Stem Cell Secretome from Star‐Shaped Poly(ethylene glycol) Glycosaminoglycan Hydrogels Promotes Motor Improvements after Complete Transection in Spinal Cord Injury Rat Model
Authors: Deolinda Silva, Lucas Schirmer, Tiffany S. Pinho, Passant Atallah, Jorge R. Cibrão, Rui Lima, João Afonso, Sandra B‐Antunes, Cláudia R. Marques, João Dourado, Uwe Freudenberg, Rui A. Sousa, Carsten Werner, António J. Salgado
Journal: Advanced Healthcare Materials (2023)

Abstract Adipose tissue‐derived stem cells (ASCs) have been shown to assist regenerative processes after spinal cord injury (SCI) through their secretome, which promotes several regenerative mechanisms, such as inducing axonal growth, reducing inflammation, promoting cell survival, and vascular remodeling, thus ultimately leading to functional recovery. However, while systemic delivery (e.g., i.v. [intravenous]) may cause off‐target effects in different organs, the local administration has low efficiency due to fast clearance by body fluids. Herein, a delivery system for human ASCs secretome based on a hydrogel formed of star‐shaped poly(ethylene glycol) (starPEG) and the glycosaminoglycan heparin (Hep) that is suitable to continuously release pro‐regenerative signaling mediators such as interleukin (IL)‐4, IL‐6, brain‐derived neurotrophic factor, glial‐cell neurotrophic factor, and beta‐nerve growth factor over 10 days, is reported. The released secretome is shown to induce differentiation of human neural progenitor cells and neurite outgrowth in organotypic spinal cord slices. In a complete transection SCI rat model, the secretome‐loaded hydrogel significantly improves motor function by reducing the percentage of ameboid microglia and systemically elevates levels of anti‐inflammatory cytokines. Delivery of ASC‐derived secretome from starPEG‐Hep hydrogels may therefore offer unprecedented options for regenerative therapy of SCI.
Dual-sized hollow particle incorporated fibroin thermal insulating coatings on catheter for cerebral therapeutic hypothermia
Authors: Ming Li, Yuan Gao, Miaowen Jiang, Hongkang Zhang, Yang Zhang, Yan Wu, Wenhao Zhou, Di Wu, Chuanjie Wu, Longfei Wu, Luzi Bao, Xiaoxiao Ge, Zhengfei Qi, Ming Wei, Ang Li, Yuchuan Ding, Jicheng Zhang, Guangzhen Pan, Yu Wu, Yan Cheng, Yufeng Zheng, Xunming Ji
Journal: Bioactive Materials (2023)

Selective endovascular hypothermia has been used to provide cooling-induced cerebral neuroprotection, but current catheters do not support thermally-insulated transfer of cold infusate, which results in an increased exit temperature, causes hemodilution, and limits its cooling efficiency. Herein, air-sprayed fibroin/silica-based coatings combined with chemical vapor deposited parylene-C capping film was prepared on catheter. This coating features in dual-sized-hollow-microparticle incorporated structures with low thermal conductivity. The infusate exit temperature is tunable by adjusting the coating thickness and infusion rate. No peeling or cracking was observed on the coatings under bending and rotational scenarios in the vascular models. Its efficiency was verified in a swine model, and the outlet temperature of coated catheter (75 μm thickness) was 1.8-2.0 °C lower than that of the uncoated one. This pioneering work on catheter thermal insulation coatings may facilitate the clinical translation of selective endovascular hypothermia for neuroprotection in patients with acute ischemic stroke.
Enzyme-triggered deep tumor penetration of a dual-drug nanomedicine enables an enhanced cancer combination therapy
Authors: Lei Gu, Zhenyu Duan, Xue Li, Xin Li, Yinggang Li, Xiaoling Li, Gang Xu, Peng Gao, Hu Zhang, Zhongwei Gu, Jie Chen, Qiyong Gong, Kui Luo
Journal: Bioactive Materials (2023)

Cancer cells could be eradicated by promoting generation of excessive intracellular reactive oxygen species (ROS) via emerging nanomedicines. However, tumor heterogeneity and poor penetration of nanomedicines often lead to diverse levels of ROS production in the tumor site, and ROS at a low level promote tumor cell growth, thus diminishing the therapeutic effect of these nanomedicines. Herein, we construct an amphiphilic and block polymer-dendron conjugate-derived nanomedicine (Lap@pOEGMA-b-p(GFLG-Dendron-Ppa), GFLG-DP/Lap NPs) that incorporates a photosensitizer, Pyropheophorbide a (Ppa), for ROS therapy and Lapatinib (Lap) for molecular targeted therapy. Lap, an epidermal growth factor receptor (EGFR) inhibitor that plays a role in inhibiting cell growth and proliferation, is hypothesized to synergize with ROS therapy for effectively killing cancer cells. Our results suggest that the enzyme-sensitive polymeric conjugate, pOEGMA-b-p(GFLG-Dendron-Ppa) (GFLG-DP), releases in response to cathepsin B (CTSB) after entering the tumor tissue. Dendritic-Ppa has a strong adsorption capacity to tumor cell membranes, which promotes efficient penetration and long-term retention. Lap can also be efficiently delivered to internal tumor cells to play its role due to the increased vesicle activity. Laser irradiation of Ppa-containing tumor cells results in production of intracellular ROS that is sufficient for inducing cell apoptosis. Meanwhile, Lap efficiently inhibits proliferation of remaining viable cells even in deep tumor regions, thus generating a significant synergistic anti-tumor therapeutic effect. This novel strategy can be extended to the development of efficient membrane lipid-based therapies to effectively combat tumors.
3D-printed fish gelatin scaffolds for cartilage tissue engineering
Authors: Abudureheman Maihemuti, Han Zhang, Xiang Lin, Yangyufan Wang, Zhihong Xu, Dagan Zhang, Qing Jiang
Journal: Bioactive Materials (2023)

Knee osteoarthritis is a chronic disease caused by the deterioration of the knee joint due to various factors such as aging, trauma, and obesity, and the nonrenewable nature of the injured cartilage makes the treatment of osteoarthritis challenging. Here, we present a three-dimensional (3D) printed porous multilayer scaffold based on cold-water fish skin gelatin for osteoarticular cartilage regeneration. To make the scaffold, cold-water fish skin gelatin was combined with sodium alginate to increase viscosity, printability, and mechanical strength, and the hybrid hydrogel was printed according to a pre-designed specific structure using 3D printing technology. Then, the printed scaffolds underwent a double-crosslinking process to enhance their mechanical strength even further. These scaffolds mimic the structure of the original cartilage network in a way that allows chondrocytes to adhere, proliferate, and communicate with each other, transport nutrients, and prevent further damage to the joint. More importantly, we found that cold-water fish gelatin scaffolds were nonimmunogenic, nontoxic, and biodegradable. We also implanted the scaffold into defective rat cartilage for 12 weeks and achieved satisfactory repair results in this animal model. Thus, cold-water fish skin gelatin scaffolds may have broad application potential in regenerative medicine.
Table of Contents
Authors: Malene Frank, Uffe Bodtger, Lamis Yehia, Maria Centomo, Paolo Pandolfi, Nicolas Girard, Simona Borilova, Ladislav Dusek, Lenka Jakubikova, Pavel Turcani, Radoslav Matej, Ivo Hanke, Radana Dymackova, Ondrej Bilek, Norbert Pauk, Marek Svoboda, Sharyn Katz, Christopher Straus, Leonid Roshkovan, Kevin Blyth, Thomas Frauenfelder, Ritu Gill, Ferry Lalezari, Jeremy Erasmus, Anna Nowak, Victor Gerbaudo, Roslyn Francis, Samuel Armato, Conrad Falkson, Emily Vella, Peter Ellis, Donna Maziak, Yee Ung, Edward Yu
Journal: Journal of Thoracic Oncology (2023)
SDCBP promotes pancreatic cancer progression by preventing YAP1 from β-TrCP-mediated proteasomal degradation
Authors: Jing Liu, Weiwei Bai, Tianxing Zhou, Yongjie Xie, Bo Yang, Jingyan Sun, Yifei Wang, Xueyang Li, Xupeng Hou, Ziyun Liu, Danqi Fu, Jingrui Yan, Wenna Jiang, Kaili Zhao, Bodong Zhou, Shuai Yuan, Yu Guo, Hongwei Wang, Antao Chang, Song Gao, Lei Shi, Chongbiao Huang, Shengyu Yang, Jihui Hao
Journal: Gut (2023)

Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal tumour with limited treatment options. Here, we identified syndecan binding protein (SDCBP), also known as syntenin1, as a novel targetable factor in promoting PDAC tumour progression. We also explored a therapeutic strategy for suppressing SDCBP expression.We used samples from patients with PDAC, human organoid models, LSL-KrasG12D/+mice, LSL-Trp53R172H/+ and Pdx1-Cre (KPC) mouse models, and PDX mouse models. Immunostaining, colony formation assay, ethynyl-2-deoxyuridine incorporation assay, real-time cell analysis, cell apoptosis assay, automated cell tracking, invadopodia detection and gelatin degradation assays, coimmunoprecipitation, and pull-down assays were performed in this study.The median overall survival and recurrence-free survival rates in the high-SDCBP group were significantly shorter than those in the low-SDCBP group. In vitro and in vivo studies have demonstrated that SDCBP promotes PDAC proliferation and metastasis. Mechanically, SDCBP inhibits CK1δ/ε-mediated YAP-S384/S387 phosphorylation, which further suppresses β-TrCP-mediated YAP1 ubiquitination and proteasome degradation by directly interacting with YAP1. SDCBP interacts with the TAD domain of YAP1, mainly through its PDZ1 domain. Preclinical KPC mouse cohorts demonstrated that zinc pyrithione (ZnPT) suppresses PDAC tumour progression by suppressing SDCBP.SDCBP promotes the proliferation and metastasis of PDAC by preventing YAP1 from β-TrCP-mediated proteasomal degradation. Therefore, ZnPT could be a promising therapeutic strategy to inhibit PDAC progression by suppressing SDCBP.
Macrophages and bone metastasis
Authors: Diletta Di Mitri, Fabio Conforti, Alberto Mantovani
Journal: The Journal of Experimental Medicine (2023)

In the prostate bone metastasis microenvironment, macrophages activate a cascade that involves Activin A, the extracellular matrix, and SRC kinase and drives resistance to anti-androgen therapy. These findings (Li et al., 2023. J. Exp. Med.https://doi.org/10.1084/jem.20221007) have broad implications, including metastasis diversity in different tissue milieus and the interplay between hormones and immunity.
Treat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica
Authors: Christian Dejaco, Andreas Kerschbaumer, Daniel Aletaha, Milena Bond, Elvis Hysa, Dario Camellino, Lisa Ehlers, Andy Abril, Simone Appenzeller, Maria C Cid, Bhaskar Dasgupta, Christina Duftner, Peter C Grayson, Bernhard Hellmich, Alojzija Hočevar, Tanaz A Kermani, Eric L Matteson, Susan P Mollan, Lorna Neill, Cristina Ponte, Carlo Salvarani, Sebastian Eduardo Sattui, Wolfgang A Schmidt, Philip Seo, Josef S Smolen, Jens Thiel, Carlos Enrique Toro-Gutiérrez, Madeline Whitlock, Frank Buttgereit
Journal: Annals of the Rheumatic Diseases (2023)

Objectives To develop treat-to-target (T2T) recommendations in giant cell arteritis (GCA) and polymyalgia rheumatica (PMR). Methods A systematic literature review was conducted to retrieve data on treatment targets and outcomes in GCA/PMR as well as to identify the evidence for the effectiveness of a T2T-based management approach in these diseases. Based on evidence and expert opinion, the task force (29 participants from 10 countries consisting of physicians, a healthcare professional and a patient) developed recommendations, with consensus obtained through voting. The final level of agreement was provided anonymously. Results Five overarching principles and six-specific recommendations were formulated. Management of GCA and PMR should be based on shared decisions between patient and physician recognising the need for urgent treatment of GCA to avoid ischaemic complications, and it should aim at maximising health-related quality of life in both diseases. The treatment targets are achievement and maintenance of remission, as well as prevention of tissue ischaemia and vascular damage. Comorbidities need to be considered when assessing disease activity and selecting treatment. Conclusion These are the first T2T recommendations for GCA and PMR. Treatment targets, as well as strategies to assess, achieve and maintain these targets have been defined. The research agenda highlights the gaps in evidence and the need for future research.